04/11/2025
💊 Ensuring access to safe, effective, and affordable medicines and vaccines is a cornerstone of Africa and Europe’s work together.
🔎 Regulatory authorities like SAHPRA are essential to keeping people healthy, and they are key partners in the Team Europe Initiative on the AU-EU Health Partnership.
Today, in the lead-up to the 3rd AU-EU High-Level Steering Meeting on the AU-EU Health Partnership on November 5th, a delegation from met with the leadership team of SAHPRA to discuss our work together, including SAHPRA’s progress towards achieving the highest level of regulatory maturity (ML4) by 2027 and being recognized as a WHO Listed Authority (WLA). This means global recognition, faster approvals and market access - attracting investment and boosting local manufacturing for export.
Through its collaboration with the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+), SAHPRA is strengthening its role in advancing regulatory excellence and contributing to a more resilient health ecosystem.
Key Takeaways included:
🟡 Supporting Local Growth: SAHPRA is dedicated to creating an enabling environment that empowers the local manufacturing sector and drives investment
🟡 Driving Efficiency and Excellence: By striving toward WLA and ML4 status, SAHPRA aims to be more responsive, efficient, and aligned with the evolving needs of the industry.
🟡 Innovation for the Future: SAHPRA is positioning itself as a world-class regulator through the adoption of AI and digitalisation as key tools for transformation.
🟡 Promoting Regional Harmonisation: SAHPRA is working with partners across Africa to align regulatory processes and build stronger regional cooperation
Learn more about SAHPRA ➡️ https://bit.ly/sahpra-home
Learn more about the SAVax program, which collaborates with SAHPRA under the Team Europe Initiative MAV+ ➡️ https://www.giz.de/en/projects/vaccines-africa-roll-out-and-production-south-africa-savax